reason report
assembl hbv cure strong posit promis new class
poc
bottom line initi coverag
outperform rate price
valuat rate base probability-adjust valu
cash flow expect lead asset oral
protein alloster modifi cpam phase ii develop
chronic hepat viru hbv forecast launch
grow risk-adjust revenu forecast base
proposit cpam success clear viral replic
sourc cccdna hepat liver provid virolog cure
accomplish current standard-of-car oral nucleot ide
revers transcriptas inhibitor nuc termin cccdna allow
patient stop treatment altogeth elimin risk transmiss
significantli reduc risk develop liver cirrhosi
cancer benefit goal cure achiev drive
high patient physician payer adopt class current
valuat target price base probability-
of-success achiev goal one portfolio
cpam one-ind one-strategi bet outcom
anyth less virolog cure littl valu compani
advanc develop program diseas foci mitig
downsid failur hand success could reward
pharmasset-lik return
near-term phase ii catalyst expect easl april
assembl current enrol two phase ii trial
treatment-nav treatment-experienc hbv patient
test combin nuc nuc alon
variou endpoint demonstr superior combin viral
biomark reduct interim look data expect
shown european associ studi liver easl
meet april provid clear catalyst could
increas consensu probability-of-success program drug
assembl posit first-to-market cpam new fda
develop guidelin assembl neck-and-neck develop
cpam op roch view high probabl
first-to-market given assembl stronger understand dose
exposur safeti sole focu therapeut area
path market approv appear fast new fda guidanc allow
approv base superior nuc monotherapi hbv dna
suppress result less persuas physician
show cpam cur phase trial could
dcf wacc
termin growth rate
year price history/av daili volume mil
creat bluematrix
compani inform leerink partner llc research
revenu mm
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
extend test virolog cure off-therapi viral suppress
label could updat reflect outcom
assembl current develop timelin suggest could translat
approv late earliest label reflect cur
outcom potenti
antivir potenc key achiev virolog cure cpam
hbv cure achiev cccdna replic factori
destroy within infect cell avail nuc fail elimin
viral replic thu constant low suppli new cccdna
avail infect persist howev addit cpam
complet suppress viral replic pre-clin experi
cpam monotherapi phase studi shown slightli
potent antivir activ nuc monotherapi assembl proprietari
data suggest exist cccdna die within week
anticip cpam-nuc combin block resuppli new
cccdna thu result increas rate virolog cure fix
rel short month less durat treatment
cpam conveni toler offer competit advantag
increasingli crowd hbv develop landscap multipl
mechan explor chronic hbv includ rnai
therapeut immunomodul howev mainstay treatment
chronic viral infect alway safe oral medicin bar
set even higher hbv alreadi effect low cost gener
nuc dose safe extend period otherwis rel
healthi individu provid substanti reduct risk
progress hbv new treatment modal hbv need
someth nuc dont mean stop treatment
elimin remain viral reservoir meet hurdl
cpam could prefer add-on class base oral dose
lack off-target toxic mechan prove effect
drug class like distinguish potenc
conveni race ideal drug asmb broad portfolio
competit advantag
multipl shot goal expand pipelin cpam
asmb lead drug begun phase ii trial assembl
also advanc two potent cpam phase ia abi-
pre-ind provid investor downsid protect
lead molecul fail drug-rel advers event fall short
competitor medicin lower efficaci potenc develop
multipl compound singl high valu target specif
viral indic similar approach taken success
pharmasset hcv
valuat base sole cur treatment opportun
hbv market model assum cpam captur
substanti share use new expand cur hbv
market base oral conveni like superior safeti
profil believ could launch us late
unadjust sale grow peak
compani model use probability-of-success abi-
us eu japan china forecast
compani reach break-even forecast cash flow year
termin growth rate captur residu patent year
pipelin discount cash flow combin
forecast cash reach equiti valu assembl stock
assembl bioscienc clinic stage biopharmaceut compani develop novel treatment
chronic hepat hbv lifelong diseas affect estim individu
global least develop market north america europ japan view
assembl leader new investig class antivir core protein alloster
modifi cpam given manag deep experi diseas first-mov advantag
broad portfolio cpam cpam shown potent current approv
nucleot ide revers transcriptas inhibitor nuc viral suppress unlik nuc cpam
design intend elimin final reservoir hepat viru liver thu
convert patient virolog control treatment virolog cure treatment hurdl
posit high progress higher rate off-treat virolog cure would
result rapid broad adopt global even treatment durat longer
exampl current hcv regimen week assembl cpam portfolio consist lead
two follow-on compound show critic proof concept activ
assum success expedit develop could receiv first approv
improv cure rate peak hbv market today could expand
base histor treatment trend cur hepat hcv market one-
indic one-strategi bet outcom anyth less virolog cure littl
valu compani advanc develop program diseas foci mitig
downsid failur hand success could reward pharmasset-lik
assembl bioscienc overview hbv strategi straight
leerink take-away assembl leverag decad proprietari hbv research
renown univers lab direct involv lab primari research
assembl bioscienc indiana-bas clinical-stag biotechnolog compani two
distinct drug platform consist clinical-stag hepat viru hbv program
preclin microbiom program significantlik entireproport assembl market
valu attribut compani hbv program compon
invest thesi hepat highli infecti blood-born viral infect liver
turn chronic diseas devast long-term liver diseas outcom chronic
infect suppress low level activ current oral antivir medicin
typic latent viru surviv circular coval close dna cccdna liver cell
hepatocyt reactiv treatment stop
current less treat patient ever cure viru long-term use
avail oral medic lack cure contribut rel low penetr
avail drug class util current treatment option interferon nuc virolog
control slow progress hbv-induc damag liver requir continu
treatment low probabl function cure elimin activ viral infect
transmiss risk persist latent viral dna liver
assembl investig hbv drug member new class oral antivir call core
protein alloster modul cpam drug novel mechan action compar
current antivir drug potenti increas effect antivir therapi
result materi higher proport patient achiev virolog cure assembl
multipl competitor advanc cpam proof-of-concept clinic trial assembl
potenti get first approv class ultim also emerg best-in-class
profil hbv import field biopharma research right sever mechan
also explor similar goal includ rna interfer rnai new
immunomodul first major valid point cpam assembl phase ii
data expect report import mileston field includ phase
phase ii data releas roch jnj cpam expect next month
far cpam shown potent independ anti-vir activ hbv
clinic evid increas cure rate still month away strategi
cure combin cpam nuc avail low cost gener order
maxim antivir potenc prevent viru develop mutat confer drug-
resist combin achiev increment on-treat viral suppress without
cure allow treatment withdraw without relaps believ cpam
wide adopt valuabl avail gener hbv antivir alreadi safe
effect vast major patient hard see brand cpam would captur
share add-on given profil
creat signific valu assembl need demonstr materi higher rate cure
exist treatment ideal rel short period time month
maxim activ assembl also need remain first- best-in-class compar
multipl known competitor cpam although even posit class
could result viabl acquisit opportun investor pre-clin profil assembl
lead cpam follow-up compound early-mov advantag support
potenti superior
assembl built hbv antivir research
assembl young compani origin form privat compani
name assembl pharmaceut compani strategi focu therapeut
innov deriv hbv research culmin indiana univers lab run
adam zlotnick ph dr zlotnick publish research hbv sinc
play major role elucid biolog viral capsid assembl dr zlotnick also
founder assembl pharmaceut current owner though current
manageri role compani lab produc patent cover aspect hbv treatment
cpam licens assembl pharmaceut assembl pharmaceut
also co-found lopatin current chief medic offic owner
mani year experi work viral program biopharma compani third co-
founder biotechnolog entrepreneur derek small current chief execut offic
owner two final co-found lilli execut academ chief scientif
offic richard dimarchi ph current director owner research scientist
william turner sinc compani incept founder join hepat drug
develop richard colonno ph instrument discoveri develop
baraclud nuc antivir bristol
assembl pharmaceut merg public trade bioscienc
combin compani name inc trade
ticker merger brought microbiom program licens
compani call therabiom howev first strateg prioriti merg
assembl bioscienc hbv program
shortag demand new estim suggest near
leerink take-away chronic hbv larg market signific unmet need
cur therapi shortag patient treat cpam us
europ develop emerg market long efficaci
compel least cure rate initi access unrestrict
accur estim chronic hbv preval nation global notori hard
determin although ballpark estim nation survey like direct
accur estim global preval hbv infect rang million
million develop countri patient access hbv medicin estim
often limit non-repres sampl popul hbv infect quickli
becom outdat due immigr pattern extrem exampl case
import case chronic hbv us asian-born immigr past
perhap reliabl estim global preval hcv estim
publish polari observatori collabor lancet studi use rigor
model process input literatur meta-analysi studi direct cooper
form nation govern result model produc global preval individu
estim countri polari studi conclud global chronic hbv
preval correspond infect
number global infect incred larg number infect individu
rel smaller countri access drug price power strongest
unit state europ japan polari studi determin preval chronic
hbv across western european countri unit state
estim equat patient us patient western europ
polari group also abl estim proport patient would meet treatment
elig defin hbv serum dna iu/ml liver cirrhosi
treatment-elig patient estim us
estim elig treatment high viral load iu/ml liver diseas
previous state effect hbv vaccin immigr pattern radic
alter us patient demograph mix past decad implic
assess commerci opportun new hbv drug includ cpam research
incorpor us nation health nutrit examin survey nhane data
suggest current us hbv infect foreign-born individu primarili
non-hispan asian proport total hbv infect white black ethnic
america respect robert et al hepatolog research
immigr pattern suggest addit foreign-born person unit
state chronic hbv top common popul estim suggest polari
estim may low kowdley et al hepatolog true preval chronic hbv
us potenti sever million individu
preval chronic hbv estim much higher certain asian countri
preval china reach infect result nearli world
hbv infect individu estim resid china assembl establish offic
shanghai begin develop gigant market expect initi progress
slow comparison gilead final receiv approv hcv medicin sovaldi china
four year origin us approv price
discount price us
japan market gener materi portion hepat hcv drug sale past
year estim chronic hbv infect treatment-elig
japanes govern decid treat hbv cur therapi manner
hcv treat major diagnos patient would treat within first
year avail thu gener substanti earli product sale
regardless exact size patient popul larg unmet need hbv cure
compel market opportun novel mechan howev new drug
expens patient requir adequ insur coverag afford treatment
unit state nhane data report infect individu insur
privat insur combin medicar medicaid exhibit result
major diagnos patient like access expens specialti drug hbv
cpam becom avail issu uptak new treatment hbv
appear current futur insur coverag instead depend level
efficaci benefit treatment result rate cure see much less adopt
reach treat patient insur statu potenti under-repres
foreign-born popul less well known reason assum poorer
exhibit unit state hbv ethnic insur mix
leerink take-away rich studi natur histori liver outcom chronic
hbv patient elucid risk factor drive treatment elig statu
dynam remov treatment uncertainti new class effect therapeut
assembl cpam
hepat defin inflamm liver case hbv inflamm driven
immun respons infect hbv double-strand dna viru genu
orthohepadnaviru origin viru unknown epidemiolog studi suggest
exist ten thousand year gerlich virol upon diagnosi hbv
classifi form viral hepat test patient blood detect specif part
viru associ antibodi viru multipl genotyp transmitt
human via infecti blood bodili fluid infect also pass
infect mother child known vertic transmiss origin
preval infect world today effect newborn vaccin
avail decad develop countri nearli elimin vertic transmiss
horizont transmiss younger gener larg reservoir infect individu
persist mani decad come
hbv infect classifi either chronic acut latter associ gener
sick jaundic week month spontan clearanc individu
immun system chronic form hbv curabl initi caus individu
immun toler structur viru protein variabl period time follow
initi infect initi period hbv replic infect spread
liver damag caus liver eventu chronic hbv patient enter
immun activ phase immun system recogn fight viru
liver becom inflam damag result chronic inflammatori process
subsequ phase patient achiev immun control viru
chronic diseas state oscil period high low viral replic high
low inflammatori respons chronic hbv patient immun respons
partial efficaci sinc lower hbv viral load marker infect
clear infect outright rather steadi suppli new infect liver cell emerg
target immun system becom part chronic hepat
process liver diseas long term neg outcom cirrhosi cancer transplant
caus chronic inflammatori respons viral infect antigen
natur histori hbv suggest risk develop chronic infect low adult
infect horizont transmiss ever clear viru
chronic state occur given exist continu liver inflammationeven ultra-low
level long period timeth outcom patient chronic hbv cours
lifetim grim base cohort studi chronic hbv patient estim
develop cirrhosi time develop hepatocellular carcinoma within year
cirrhot liver quickli lead decompens liver failur quarter patient
liver cancer major caus liver transplant death hbv patient exhibit
exhibit risk progress chronic hbv infect
sundaram kowdley bmj
though presenc neg liver outcom chronic hbv patient recogn
decad degre risk confirm risk evalu viral load elev
associ liver disease/cancer-hepat viru reveal-hbv studi carri taiwan
reveal prospect natur histori studi recruit
particip taiwan individu determin hbv-posit hcv-
neg hbv patient follow examin hbv
biomark incid cirrhosi data determin hbv patient
lifetim risk develop risk note non-carri popul
term death hazard ratio hbv carrier estim
increas risk death reveal data also determin lifetim risk hcv patient
develop cirrhosi approxim nearli half chronic hbv patient
crown achiev reveal discoveri biomark associ elev
outcom risk cumul risk cirrhosi highli correl serum
hbv dna level reveal studi group patient base serum hbv dna baselin
copies/ml hbv dna copies/ml case significantli higher
independ lifetim risk associ patient serum hbv dna copies/ml
specif patient hbv dna level threshold lifetim risk
versu patient threshold lifetim risk cirrhosi
compar patient threshold exhibit
exhibit lifetim hbv patient risk progress serum dna level
chen yang journal gastroenterolog hepatolog
sinc current antiretrovir therapi suffici reduc hbv dna level well
copies/ml benefit treatmentand cost treatment avoidancear well understood
treatment guidelin vari issu agenc base risk factor liver
diseas progress discov reveal-hbv studi anti-retrovir therapi
recommend patient high serum hbv dna level order reduc risk liver
event practic measur hbv dna copies/ml translat valu
iu/ml standard blood test
goal treat hbv two-fold patient treatment aim prevent
hepatocellular carcinoma liver decompens public health treatment aim
reduc transmiss incid new chronic case said major hbv
patient low hbv dna level undamag liver remain off-treat requir
appar benefit risk reduct treatment absenc elev viral
load guidelin also stress hbv dynam diseas patient fluctuat
differ level hbv dna viral serum marker test guidelin
also detail qualit group high-risk individu regularli screen hbv
level suggest treatment necessari certain patient higher level viral
cutoff treatment often iu/ml low iu/ml higher-risk
patient lack hbv biomark certain hepat e-antigen mutat viru
guidelin also suggest evalu alanin aminotransferas alt compar normal
level assess degre liver injuri patient respond well antivir therapi
guidelin offer option stop therapi also recommend continu therapi higher-
risk patient given accept long-term safeti avail medicin near-
certainti virolog relaps treatment discontinu
import recogn guidelin establish respons
therapeut armamentarium produc reliabl cure guidelin would
like use triag immedi treatment highest risk individu subsequ
novel hbv therapi includ cpam new drug produc clinic meaning
improv cure rate would expand treat popul chronic hbv patient
enhanc cure rate would also propel diagnost test initi similarli
occur hcv would like result increas number diagnos
treatment elig patient
target drug
facilit viral replic spread infect protein logic target
new hbv medicin direct overlap current therapi
treat and/or cure hbv function understand physiolog viral life-cycle put
simpli hepat viru abl self-repl within infect liver cell deploy
combin viral protein gener dna blueprint host protein drug step
along replic chain inhibit process suppress viral activ reduc
elimin patient damag immun respons could potenti cure viral
infect time
hepat viru double-strand relaxed-circular rc dna viru enter host
surround nucleocapsid core particl outer envelop cover surfac
protein viru enter liver cell hepatocyt outer shell remov
nucleocapsid remov viral dna transfer cell nucleu insid nucleu
natur liver cell enzym link rcdna strand coval close circular dna cccdna
intra-nuclear viral cccdna exist apart host dna mini chromosom
cccdna remain infect cell unknown period becom templat
synthesi viral pregenom pg rna serv translat templat rna
polymeras core protein cccdna also produc transcript addit viral protein
aid replic
newly-mad viral pgrna transport nucleu cell cytoplasm host
cell whereupon packag core protein new viral nucleocapsid new capsid
also includ viral polymeras revers transcriptas turn packag
pgrna double-strand rcdna viral genom ident origin viru enter
cell point nucleocapsid either re-ent cell nucleu provid continu
replenish cccdna within infect cell gain new outer envelop exit
liver cell find new hepatocyt target exhibit
exhibit hepat life-cycle involv protein
surviv viru within infect liver cell abil replic infect cell
individu depend maintain reservoir cccdna reservoir
antivir treatment intend elimin viru also infect liver cell dna
viru becom integr host cell genom integr process occur
revers transcript process randomli creat double-strand linear dna integr
host dna mechan time well understood integr hbv
dna capabl produc viral protein importantli never shown produc
complet hbv virion capabl infect thu integr hbv dna
shown caus hbv replic logic target hbv cure cccdna
integr hbv dna integr hbv dna complic diagnost test howev
well document cell produc hepat surfac antigen viral particl
therefor patient blood test may still show presenc hepat surfac antigen
indic chronic infect cccdna hypothet clear novel medicin
drug current avail target destroy exist cccdna infect cell
multipl therapeut approach focus drug differ step along hbv replic
cycl drug would prevent resuppli cccdna within infect cell infect
neighbor cell complet blockad replic natur turnov exist
cccdna time would end abil viru replic culmin effect
elimin viru cure achiev cure replic process need
suppress certain durat time effect starv exist cccdna
outcom could achiev even presenc residu integr hbv dna
replic virion unfortun half-lif cccdna clear subject debat
expert believ drug treatment need cover least sever half-liv cccdna
achiev cure signific proport treat patient answer direct implic
requir durat therapi cpam question requir durat drug
exposur one key controversi assembl stock see section
leerink take-away viabil cpam cure rate assess phase iia data
view common blood test biomark assembl first begin collect
biomark data offer clear catalyst stock
clinic diagnosi monitor hbv simplifi viru on-going secret
larg amount complet incomplet viral particl circul patient clinic
practic chronic hbv screen diagnos physician use sever simpl
commodit blood test test hundr dollar wide cover
insur turnaround result occur within day viral particl provid
physician biomark measur state stage infect damag
inflict liver turn help assess patient risk statu need antivir
therapi biomark also use clinic endpoint investig hbv drug
must understood contextu opportun assembl new medicin data
use predict biomark level hbv dna hbv rna hbv surfac
antigen hbsag hbv e-antigen hbeag although multipl biomark exist exhibit
test hbv dna viral load measur actual amount complet viral particl
blood sampl level high test help physician determin viru activ
replic liversom secret bloodand patient highli
contagi reduc hbv dna level lower limit quantif
remain accept primari endpoint pivot trial indic near complet
cessat viral reproduct howev sensit assay complet patient
undetect hbv dna level may ultra-low persist viral replic
on-going intrahepat creation virion resuppli cccdna hbv rna test offer
upstream view viral replic packag pgrna undergon revers transcript
also secret infect cell nuc treatment typic affect rna level
short term drug mechan prevent revers transcript high level hbv
rna suggest cccdna activ initi replic process produc transcript
reduct rna level could associ reduct cccdna level
hbeag protein manufactur secret viru replic
thought down-regul immun respons viru circul also indic
viru multipli howev mani individu chronic hbv eventu lose e-
antigen circul due develop hbeag antibodi anti-hb process
call seroconvers seroconvers suggest immun system activ keep
viru control import note viru continu replic hbeag-
neg patient reactiv phase thu concurr hbv dna test import
put context whether patient hbeag-posit hbeag-neg hbeag-neg
risk liver-rel event lower hbv dna threshold
exhibit list hbv biomark clinic import red
final hbsag non-infecti structur protein part protect envelop
surround viral dna first serolog biomark appear infect
posit test month initi infect confirm chronic hbv infect on-going
loss hbsag rare occurr chronic hbv typic associ product
surfac antibodi anti-hb hbv viru necessarili fulli clear liver
state indic full control infect immun system without need
medic therefor hbsag clearanc indic prevent futur re-infect risk
self other consid function cure patient hbsag sero-clear also
consid materi lower risk hbv-relat complic includ cirrhosi
hepatocellular carcinoma liver failur next meaning threshold hbv
treatment inhibit viral load howev goal cpam go one step beyond
threshold complet remov cccdna liver
assembl cpam current test combin nuc two phase ii
trial describ detail determin drug impact level hbv dna rna
hbeag hbsag week declin hbsag import assembl studi
consid ultim marker success current therapi hbsag
declin due deplet cccdna sourc antigen product abi-
would elimin potenti hbsag sourc integr dna within month
phase ii result first avail data continu matur
patient enter open-label period provid investor addit updat medic
confer open label extens incorpor longer durat
treatment initi studi like address question hbsag loss
relat cure expect result open label extens arm disclos
current hbv drug leav plenti opportun improv
leerink take-away inabl current antivir cure patient offer market
opportun new potent class cpam nuc set high bar
safeti efficaci evidenc low uptak toxic interferon treatment
eight medic across two drug class approv treatment chronic hbv
exhibit commonli use drug hbv oral antivir agent nucleo ide
revers transcriptas inhibitor nuc class includ bristol baraclud entecavir
gilead viread tenofovir avail gener howev new version
gilead tenofovir alafenamid recent approv vemlidi hbv vemlidi
superior safeti profil long-term use drive signific market share gain
product nuc entecavir often consid standard care new treatment-nav
patient viread/vemlidi commonli use patient prior nuc exposur drug
work competit inhibit revers transcriptas enzym also call polymeras
build new viral dna viral pgrna specif nuc nucleo ide analog
compet natur nucleo ide incorpor viral dna built enzym
nuc integr natur nucleo ide longer ad grow chain
viral replic process abort
second group drug approv hbv immunomodul stimul
immun system fight viru use immunomodul name pegasi pegintron
pegyl interferon declin dramat past year drug confer
margin higher chanc achiev cure come substanti toxic burden
requir extend durat treatment mainten therapi pegasi achiev nearli
peak annual histor sale believ vast major use product
hcv indic annual revenu deriv hbv patient
pegasi experi demonstr new hbv drug must provid increment cure
benefit without addit toxic must induc groundbreak cure rate off-set potenti
exhibit fda approv treatment chronic hepat infect
unlik interferon latest gener nuc well-toler suitabl long-term
therapi util nuc rare ever undermin develop viral resist
mutat result patient manag chronic nuc without major issu
nuc also effect achiev intend purpos reduc viral replic
measur elev hbv dna level undetect level drastic reduc life-
time risk cirrhosi demonstr reveal studi sinc replic
process block cccdna produc viral rna hbv rna level normal
unaffect nuc
hbv dna level one year baraclud viread bring hbeag-posit
patient level undetect hbv dna hbeag-neg patient typic start
low baselin viral load reach undetect level hbv dna one year
result reduc viral load continu hbv infect reveal studi indic
hbv patient still life-tim risk cirrhosi
respect nuc also normal alt level hbeag-posit patient
hbeag-neg patient suggest drug reduc liver damag
march toward liver fibrosi nuc induc hbeag seroconvers
patient within one year longer term therapi howev drug offer low
rate hbsag sero-clear function cure almost patient continu carri
viru risk viral replic flare therapi stop exhibit
exhibit efficaci data nuc
one reason nuc achiev higher degre function cure drive patient
complet cure thought lack complet antivir potenc new class
cpam may address exhibit nuc proven gener potent drug hbv dna
reduct knowledg true efficaci limit sensit assay avail
test hbv dna level human blood sampl assay lower limit
quantif lloq unit level hbv may still replic liver
cell despit appar undetect serum assay
proport hbv dna undetect hbv dna undetect chang eag hbsag hbv dna undetect hbv dna undetect chang eag hbsag inc
exhibit degre efficaci achiev current futur hbv therapi
inde recent evid preclin test human liver cell line conduct
assembl demonstr ultra-low level viral replic continu nuc
treatment entecavir assembl research shown cpam potent nuc
higher drug concentr synergist antivir effect observ nuc
combin cpam extent combin drove complet hbv dna reduct
bioassay use screen inhibitor hbv replic exhibit
exhibit viral dna reduct nuc cpam liver cell line
evid increas potenc cpam compel believ
market class base enhanc viral suppress on-therapi alon rather
increas antivir activ cpam new drug class hbvmust translat
increas e-antigen seroconvers higher cure rate defin viral suppress off-
therapi maintain excel safeti profil conveni dose unlik interferon
exhibit expect profil new hbv medicin
nucleosid revers transcriptas inhibitor protein alloster modulatorsrnaiexcel hbv dna suppress -- -- poor hbv rna suppressionincreas hbv rna suppressionpoor e-antigen seroconversionincreas e-antigen seroconversionvirtu surfac antigen clearanceincreas surfac antigen clearancein directli destroy hbv cccdna -- -- chronic treatment requiredavail treatment cessat holidaysexcel safeti profilemust maintain safeti profilehigh conveniencemust maintain convenienceattribut optim treatmentsattribut current treatment assembl bioscienc inc
novel potent cpam could enhanc hbv treatment
leerink take-away cpam mechan distinct current approv hbv
medicin could lead synergist efficaci includ cure
preclin data also suggest cpam potent nuc
mechan core protein alloster modul cpam assembl
directli affect capsid stabil assembl crucial step hbv replic cycl
pgrna encapsul core protein hbv core protein tightli regul
undergo alloster conform chang order particip self-assembl
format viral capsid around revers transcriptase-vir rna complex alloster
modul disrupt process alter physiolog core protein cpam gener
caus disrupt bind core induc rapid capsid assembl lead
product error capsid product empti capsid cpam known
exclus produc two type outcom consist empti capsid normal geometri
size class cpam empti capsid abnorm geometri size class ii cpam
cpam best thought drug send viral assembl overdr lead capsid
product failur similar outcom conveyor system manufactur plant sped-
without adjust factori machineri antivir properti cpam specif due
failur abnorm capsid process viral replic pgrna revers transcript
depend upon signal function core protein similar nuc blockag revers
transcript lower amount hbv dna patient howev cpam act upstream
nuc potenti potent antivir nuc assembl demonstr
signific reduct cccdna preclin hepat cell line cpam treatment
achiev nuc treatment high concentr similar assay exhibit furthermor
rapid rebound viral replic patient nuc monotherapi stop consist
failur reduc cccdna one critic test cpam whether rebound
occur occur fast cpam treatment
exhibit preclin assay reduct cccdna cpam nuc
cpam recogn disrupt capsid format block revers
transcript viral core protein also involv subsequ step hbv replic
process anoth one advantag class cpam disrupt multipl step
hbv replic cycl wherea nuc inhibit revers transcript second function
cpam impact viral entri cell nucleu sinc hbv rcdna enter cell
transport nucleu surround capsid made core protein cpam also disrupt
viral transport natur uncoat hbv dna exhibit could add addit
efficaci reduc abil escap virion infect neighbor cell recycl
back infect cell nucleu replenish cccdna reservoir disrupt re-
infect potenti may one biggest advantag cpam compar class
antivir protein also known bound cccdna within nucleu research
yet fulli elucid purpos set less clear outcom cpam
would produc modifi specif protein
exhibit multipl mechan action cpam
turnov cccdna build evid cpam
leerink take-away assembl rational pursu cpam base proprietari
cccdna turnov evid counter widespread assumpt hbv
cccdna long half-lif assembl assert cccdna turn
month need valid cpam produc meaning cure rate
viabl drug class short treatment durat
order hbv cure achiev without on-going treatment cpam requir
effect elimin hbv cccdna sourc viral replic sinc drug
avail directli elimin cccdna reservoir nucleus liver cell next best
approach complet prevent creation new cccdna wait exist cccdna
natur turn disappear absenc replac
starvat approach essenti strategi cpam mean cpam two
separ defin hurdl technic success order effect cure first cpam must
fulli block creation new cccdna replic superior preclin antivir profil
human evid effect could begin gather on-going phase ii trial
observ reduct hbv biomark impact nuc especi hbv rna hbsag
second exist cccdna must reason short half-lif must die complet
allow patient ceas cpam therapi maintain cure without relaps demonstr
rebound viral replic hbv dna level howev far concret evid
half-lif cccdna
accur determin half-lif viral compon within nucleu human liver cell
easi feat main obstacl studi hbv cccdna biolog requir
longitudin liver biopsi present seriou risk patient never agre
investig age univers effect nuc therapi even biopsi
sensit avail tool detect follow cccdna absolut result
research attempt use biomark presum correl cccdna level
estim half-lif cccdna clinic trial antivir nuc class correl
complic inabl approv nuc reduc circul dna level complet level
replic continu limit quantif turn suppli infect cell
new cccdna famou studi werle-lapostol colleagu look cccdna
biopsi untreat natur histori patient patient receiv weak older nuc adefovir
dipivoxil week conclud slow declin cccdna copi number would
requir decad antivir therapi fulli clear specif paper state
base mathemat model use cccdna data deriv patient
adefovir dipivoxil adv substudi would take approxim year complet
clear chronic hbv-infect human liver intracellular cccdna howev
intracellular cccdna remain detect patient resolv chronic hepat
may necessari erad complet cccdna establish long-term control
-werlelapostol et al gastroenterolog persist cccdna
natur histori chronic hepat declin adefovir dipivoxil therapi
assembl disagre view attempt go beyond function cure state
werlelapostol colleagu achiev today low singl digit percentag
treat individu
assembl stanc half-lif cccdna rang week compani
view base proprietari research use retrospect biopsi sampl hbv patient
investig compani examin liver biopsi sampl patient experienc
virolog breakthrough lamivudin studi telbivudin studi effort two
legaci antivir prone caus resist mutat would lead treatment
failur liver biopsi serum sampl uniqu sampl
longitudin period week allow assembl examin
rate extent resistance-driven viral physiolog time
first assembl sequenc popul cccdna found signific subpopul
inact cccdna molecul liver biopsi sampl least specif
achiev test allow assembl correl sequenc pgrna serum
sampl cccdna popul liver biopsi frequent blood
studi took patient lamivudine-resist hbv random
peginterferon pegasi differ nuc adv patient biopsi could
assess chang mutant pgrna popul wild-typ wt popul
baselin assembl found pgrna mutant patient treat
interferon patient experienc rapid switch wild-typ pgrna popul within
week indic cccdna must complet turn within period
chang composit pgrna sampl degre effort studi includ patient
develop viral resist telbivudin tbv week sampl taken week
assembl sequenc work found mutant pgrna dna
emerg rapidli week vast major pgrna molecul convert
wild-typ resist genotyp within week pgrna chang lag dna chang
make sens mechanist sinc patient remain nuc wild-typ dna
would effect suppress mutant version would quickli
increas popul howev nuc impact pgrna changeov would
mimic changeov cccdna driven new mutant hbv dna infect patient
exhibit kinet hbv dna rna popul changeov
support work admittedli deriv small sampl assembl phase
monotherapi trial one patient preexist resist variant cpam
enter trial patient pgrna popul move mutant mutant
day treatment line rapid kinet cccdna turnov note
older biopsi sampl turnov cccdna brief week treatment
potent cpam achiev optim exposur liver could conceiv requir month
clear viral infect
leerink take-away high-qual lead asset phase ib data
demonstr good drug properti toler hbv dna reduct align
hbv rna reduct offer proof mechan differenti
assembl lead cpam cell cultur model demonstr
abil reduc viral antigen hbeag hbsag well cccdna test initi
human safeti antivir activ assembl conduct two-part phase ib trial
first portion trial label studi test repeat dose
healthi adult volunt once-daili dose evalu
compar placebo safeti pharmacokinet second portion label studi
test repeat dose otherwis healthi non-cirrhot adult chronic hbv three
previou dose higher dose test safeti pharmacokinet antivir
potenc measur serum hbv dna level similar endpoint previou
gener nuc class exhibit healthi volunt hbv patient segment
studi complet american associ studi liver diseas
aasld annual liver meet novemb
pharmacokinet data patient healthi volunt demonstr abi-
excel drug properti instanc accumul drug
steady-st dose subject exhibit good drug absorpt drug exposur level
data also demonstr plasma exposur similar patient
healthi volunt though hbv patient demonstr small trend toward higher
exposur dose result deriv patient sampl taken day
day healthi volunt day hbv patient
hbv patient initi efficaci also posit although long-term goal
cpam increas proport hbv patient reach cure off-therapi assembl
first prove antivir properti reduc hbv dna monotherapi drug
enter trial baselin mean hbv dna level measur log iu/ml
hbeag-posit patient across treatment group hbeag-
neg patient patient posit hbeag activ replic
infect liver cell viru circul blood caus higher
efficaci data report aasld broadli demonstr four dose
monotherapi rapid potent antivir activ patient subgroup two
import caveat discuss antivir activ dose-depend best result
achiev arm dose select trial day
dose reduc mean hbv viral load approxim log hbeag-posit
patient approxim log hbeag-neg patient combin
patient group hbv dna reduct approxim log maxim reduct
hbv dna achiev individu patient arm log exhibit given
level efficaci hbv dna level reduc lower limit quantif lloq
four hbeag-neg patient
data compar like superior term speed degre efficaci
known efficaci monotherapi nuc similar treatment durat although nuc label
suggest hbv dna reduct reach log occur week wherea
patient treat week studi approv dose entecavir
test day mean chang hbv dna report log popul
hbeag-posit patient comparison hbv dna reduc similar
log hbeag-posit cohort exhibit stage
evid suggest least potent term antivir effect state
art nuc
exhibit antivir result entecavir hbeag patient
two notabl caveat phase ib hbv dna data first one
patient cohort enter known resist mutat cpam baselin
mutat residu core protein manag believ
frequenc hbv patient baseline-resist patient trial still experienc
log declin hbv dna show cpam mechan alon still benefit
patient clearli diminish respons compar mean reduct
patient without resist mutat cpam intend administ combin
therapi appar rare case sub-optimal respons avoid futur
combin use nuc viral breakthrough due resist mutat except rare
nuc nuc mechan prevent mutant viru grow popul
therefor attribut sub-optimal respons monotherapi design
believ reflect ultim efficaci given combin
expect durat month second cautionari observ less explain
fact hbeag-posit patient evid baselin resist mutat
unexpectedli weak respons drug one patient arm one
arm base rang baselin hbv dna reduct provid data set
aasld respons patient reduct log patient
reduct log trial investig note two patient could
less perfect complianc treatment may adequ exposur
reason studi pivot trial combin regimen even
increment small benefit potenti synergist nuc drive patient
cure howev materi lower antivir effect patient absenc
explan concern
cours hbv dna reduct alon indic cure achiev evidenc
inabl nuc produc outcom despit reduc dna level
level quantif on-therapi howev chang hbv rna biomark direct
product cccdna may indic potenti cur abil hbv drug
phase ib trial patient experienc steep reduct hbv rna log
dose level respons also dose-depend close mirror rate declin
hbv dna hbeag-posit patient easili quantifi level hbv rna
baselin mean rna copies/ul declin log log log cohort
respect exhibit rna reduct differenti cpam
core inhibitor reduc rna within one month increment benefit suggest
cpam could alreadi reduc suppli cccdna creat rna line
assembl view cccdna turn rapidli
safeti toler result also import sinc drug dose
least month nuc set high bar safeti futur hbv antivir overal
phase ib trial gener well toler report treatment-emerg advers
event teae grade rate mild except one grade rash exhibit
dose-limit toxic common advers event diarrhea dizzi
fatigu headach hypertens influenza-lik ill pruritu oropharyng pain one
patient grade rash dose cohort discontinu trial
rash resolv without treatment discontinu may translat small
number patient becom inelig event probabl contribut
assembl decis pursu lower dose phase ii trial dose
definit proof-of-concept data
launch possibl
leerink take-away plan phase iia studi valid asmb cpam cccdna
deplet hypothesi result expect april offer near-term stock catalyst
focu reduct serum hbv biomark
assembl initi phase iia trial summer object
trial determin magnitud decreas hbv serum biomark least month
cpam combin nuc compar nuc alon durat trial
least durat phase trial also test certain biomark becom
undetect extend treatment exposur month patient continu
combin crossed-ov placebo continu test
undetect level serum biomark patient achiev outcom remov
drug follow off-treat monitor virolog relaps first set data
focus biomark decreas avail interim data read april
full data potenti earli cure data avail
phase ii trial program initi total origin
design recruit patient hbeag-posit diseas reason exclus select
patient popul patient enter rel higher hbv serum biomark
level hbeag-neg patient allow assembl better assess antivir
activ base chang biomark howev base investig
demand assembl also open hbeag-neg cohort long-term assembl plan
conduct pivot trial hbeag-posit neg patient
one trial recruit viral suppress patient current entecavir tenofovir studi
test continu use nuc placebo addit combin
continu use nuc sinc patient level hbv dna quantif
primari outcom log chang hbv serum viral antigen hbsag hbeag
week
second studi recruit patient current nuc therapi treatment-nav
hbv viral load iu/ml hbsag iu/ml screen studi
test combin nuc compar nuc placebo primari
outcom mean log hbv dna baselin week week trial
expect complet interim data also avail april easl
result timelin phase iia program present clear import catalyst
assembl stock treatment-nav patient would expect see quicker
onset higher proport hbeag-posit patient reach undetect hbv dna level
compar nuc nuc demonstr week viral suppress
patient focu primarili degre rate declin hbsag assembl
power trial detect log declin hbsag hbeag declin biomark
would provid support assembl hypothesi cccdna deplet infect
liver cell especi sinc declin would occur patient alreadi achiev
viral suppress nuc
week treatment complet patient move open-label extens
phase continu therapi crossed-ov activ drug treatment
consolid patient test declin loss hbv dna hbeag
hbsag patient achiev undetect level hbv dna rna well either loss
low stabl level hbsag taken treatment monitor sustain viral
suppress month off-treat monitor potenti demonstr efficaci
virolog cure endpoint never achiev nuc exhibit
virally-suppress hbeag-posit hbeag-neg patient dna loqplacebo soc soc nrtiprimari endpoint chang mean serum viral antigen hbsag hbeag baselin week complet hbeag-posit patient viral load iu/ml hbsag iu/ml screeningplacebo entecavirprimari endpoint chang mean hbv dna baselin week week complet arm treatment arm assembl bioscienc inc
primari endpoint phase iia trial reach assembl plan start
phase program would expect trial recruit end
least on-treat data end six-month off-treat result avail
follow year actual primari endpoint durat phase trial abi-
still determin new fda guidanc document novel hbv medicin
suggest multipl pathway discuss comparison phase trial gilead
vemlidi follow-up nuc viread complet primari endpoint proport
patient undetect hbv dna year studi initi similar timelin would allow
launch end align current consensu estim
show revenu begin ramp
develop cpam novel class
leerink take-away recent releas fda hbv drug develop guidanc
friendli cpam oner rnai approach guidanc give
assembl secur fast-to-market full approv pathway base viral
suppress allow subsequ updat long term outcom
novemb fda releas guidanc industri assist compani
develop chronic hbv medicin entitl chronic hepat viru infect develop
drug treatment document outlin phase studi conduct show
suppress hbv dna on-treat similar current avail chronic nuc
sustain suppress month hbv dna treatment finit
durat therapi
sustain suppress month hbv dna treatment hbsag loss
less intern unit/millilit without hbsab seroconvers
finit durat therapi
guidanc also specif state hbv dna suppress without hbsag loss
consid valid surrog endpoint demonstr predict clinic
outcom endpoint could use support tradit approv emphasi ad
true outcom patient would reduct seriou hepat event could
evalu long-term follow-up clinic develop program
howev compani develop novel hbv medicin understand greatest demand
medicin advanc standard care measur cure judg
hbv viral suppress sustain treatment desir patient outcom
cure associ better clinic prognosi lower risk cirrhosi due
reduc elimin liver inflamm howev hbsag reduct without hbsag loss
known benefit unlik path forward drug approv thu far early-stag
clinic develop new hbv medicin focus declin hbsag
guidanc document clearli state viral suppress especi suppress
maintain off-therapi endpoint import
regulatori agenc also recogn new agent like combin current
standard care nuc combin therapi success hcv hiv
result regulatori agenc requir develop first studi drug monotherapi studi
henc assembl phase ib trial move phase ii combin trial final given
excel safeti toler nuc regulatori agenc close scrutin toxic
new medicin particularli increment benefit modest
guidanc document offer potenti acceler develop timelin approv
assembl conduct superior studi combin
nuc nuc monotherapi would provid adequ efficaci safeti data
drug approv potenti label would competit compel
patient payer without function virolog cure phase trial could
extend test cure off-therapi viral suppress label could
updat reflect outcom would expect uptak occur well label
updat data releas assembl current develop timelin suggest could
translat approv late earliest label reflect cur outcom
potenti
cpam landscap competit assembl potenti
best-in-class time market lead
leerink take-away least seven compani hbv cpam develop
assembl own best asset broadest portfolio
unsurprisingli compel hypothesi earli evid cpam led competit
field multipl biotechnolog compani proprietari cpam inhibitor current
stage preclin phase ii test develop asset close examin
relat assembl pipelin updat competitor could posit neg
impact valu assembl stock date awar five compani clinic
cpam three addit compani preclin asset multipl compani
includ assembl race develop second third gener version cpam
optim drug properti cpam clinic develop assembl johnson
johnson roch qilu hec pharma pre-clin compound develop
enanta arbutu shanghai zhimeng exhibit
date monotherapi cpam led hbv dna reduct log phase
larger reduct observ hbeag-posit patient expect mean reduct
note hbeag hbsag one month dose mechan
drug block cccdna replenish take longer day achiev
outcom except hec pharma first cpam produc interim
phase ii data endpoint heteroaryl dihydropyrimidin hap base clinic
candid one first gener cpam compound synthes
compound multipl issu first propos vitro potenc
immort cell line assay lost test primari hepatocyt uncultur cell
liver tissu wherea assembl compound maintain potenc across assay exhibit
burden short half-lif requir dose ritonavir booster
either twice three time day order inhibit hepat enzym improv exposur
companycpamstagedosingantivir activityhec bid tid ritnovirmean log reduct hbeag qdmean log reduct hbeag qdmean log reduct eag mean log reduct bidmedian log reduct hbeag bid inc
exhibit preclin limit human liver cell
limit need place context phase ii data faulti
phase ii studi monotherapi studi rather
combin trial nuc given suscept cpam resist without nuc
troubl exposur data unsurprisingli weak hard interpret phase ii
present aasld late-break entitl safeti pharmacokinet anti-vir
efficaci novel protein alloster modifi patient chronic hepat
interim result phase studi interim data show chaotic impact
hbv biomark patient hbeag-posit neg week
expect mean drug concentr dose fluctuat wide ng/ml
error bar wide suggest outlier patient littl much drug
common howev manag show decent antivir activ mean max hbv dna
reduct log two dose patient fell
quantif importantli also reduc hbsag log hbeag
log monotherapi week well produc log reduct hbv
rna patient achiev hbsag declin without alt flare suggest
reduct caus immun respons present report possibl
resist mutat given trial monotherapi materi increas
probabl success cpam class inform phase studi
asid lead clinic cpam own assembl roch assembl abi-
arguabl shown greatest potenc compar roch jnj compound
trial conduct small sampl day
import efficaci measur impact hbv biomark long-term
combin nuc said assembl drug demonstr lead cpam
compel potenc well-character drug properti specif limit jnj asset
long half-lif complic dose lack true dose respons
caus advanc low- high-dos phase ii transient lipid elev note
safeti result specif limit roch asset requir twice-daili dose
larg amount liver accumul requir safeti studi beyond day potenti
drug-drug interact assembl current appear pois first phase readi cpam
pend success phase iib trial next year
cpam lead increas cure know cur diseas set
drug properti suppli meaning competit advantag even absenc superior
clinic data properti includ oral avail size pill half-life/dos food
requir restrict drug-drug interact liabil overal safeti toler
compar rest cpam far well-character dose
cleanest safeti data contrast abi- jnj drug still test two dose
low high daili dose phase ii phase show dose-
depend respons impact lipid paramet roch drug requir bid
assembl also earli process develop gener cpam second
cpam enter clinic trial third iter pre-ind stage
well necessarili design increas target inhibit improv upon
potenti cure rate may increas speed declin hbv biomark
could shorten durat therapi need cure new molecul also expect
potent weight compar mean therapeut dose one-tenth
pill size next-gener advanc patient-friendli reduc
pill size potenti allow one-pil combin regimen would increas patient
complianc new molecul long patent life provid assembl
life-cycle manag strategi hbv franchis also produc potent
follow-on molecul current pre-clin earli phase trial
expect multipl data readout present cpam cours next
month base clinic trial protocol list exhibit updat primarili
center present european associ studi liver easl
intern liver congress april american associ studi liver diseas
aasld liver meet novemb
cpam rnai therapi emerg winner broad
leerink take-away multipl compani explor novel mechan treat hbv
cpam logic direct antivir approach rest clinic
pipelin requir unpredict immun respons less well-character
mechan action rnai also intrigu high safeti bar broad
popul patient
stagnat standard care treatment hbv led multipl compani
pursu treatment hypothesi beyond cpam broadli categor approv categori
investig categori hbv medicin inclus cpam exhibit
investig effort includ molecul prevent entri hepat virion new liver
cell hbsag inhibitor block secret antigen infect cell
method unlik produc durabl antivir result sinc block replic
cycl within infect cell directli stimul immun respons viru
unlik threaten cpam although may complementari
view reinforc rel number compani develop
compani classcompar cpam technolog believ
competit environ maintain develop new class
immunomodul variou technolog target viral gene express
immunomodul activ protein innat immun system toll-lik receptor
tlr retino acid-induc gene-i encourag amplifi attack viral
infect larg compani gilead roch studi asset
molecul languish clinic pipelin appear like emerg next
year approv drug therefor believ like forthcom competit
therapeut target viral rna either rna interfer rnai antisens
exhibit clinic pipelin hbv
goal cpam prevent hepat viral capsid protein properli
function goal rna-bas therapeut prevent translat hepat viral
protein therebi prevent possibl viral replic rna-bas therapeut work
degrad amount viral messeng rna mrna avail translat protein
similar cpam therapeut directli target hbv cccdna attempt cut
resuppli new infect cccdna inhibit replic process rna-bas
therapeut fall two main classif call rnai antisens oligonucleotid aso
former provid complementari rna strand load infect cell rna-
induc silenc complex risc risc natur protein use cell find destroy
rna virus silenc gene prime rnai therapeut target hbv
transcript complementari hbv strand therapeut deliv load
risc match cleav viral rna second aso mechan bind directli
target mrna block translat process mrna viral protein
induc breakdown mrna rnase enzym
hypothesi target viral replic upstream rna level attract multipl
compani field develop lead compani includ arrowhead
collabor arbutu alnylam rnai ionis/gsk roch antisens
oligonucleotid lead asset arrowhead aro-hbv subcutan rnai
interim phase i/ii data howev therapi much difficult deliv liver cell
associ toxic small molecul direct-act antivir
result three rnai program cancel past due anim death concurr
preclin test despit test human exhibit
exhibit landscap investig discontinu hbv rna therapeut
rnai aso approv indic diseas
immedi life-threaten less avail treatment altern none
compar hbv therefor safeti bar higher therapi hbv
toxic highli scrutin regul physician rnai therapeut requir
test larg number hbv patient compar rel small number test
approv indic orphan diseas creat larger chanc potenti
unknown toxic class therapeut emerg fact fda hbv guidanc requir
minimum patient expos propos dose durat treatment
companiesproducttypedeliveri platformadministrationcommentsarrowhead jaro-hbvrnaitarget rnai moleculesubcutaneousphas i/ii on-going interim hbsag nanoparticleiv infusionphas ii on-going interim hbsag declinesioni antisens oligonucleotidesubcutaneousphas ii ongoingioni antisens oligonucleotidesubcutaneousphas ii ongoingvir enhanc stabil chemistry-plu esc subcutaneousphas i/ii nucleic acidsubcutaneousphas destabilizersmal moleculeoralpreclinicaldicernadcr-hbvsrnaigalxc polyconjugateiv infusionhbsag declin clearanc cancel death nonhuman polyconjugateiv infusionhbsag declin cancel due similar focu assembl bioscienc inc
gigant clinic manufactur hurdl development rna therapi
addit fda guidanc requir bioinformat studi drug use nucleic acid
target ensur off-target toxic risk minim exhibit requir creat
difficult develop path compar tradit oral antivir cpam
exhibit fda hbv guidanc document requir rnai preclin toxic
safeti asid data date arrowhead lead program aro-hbv shown strong
reduct biomark antigen albeit earli small patient popul without
proven durabl aro-hbv rnai design silenc entir transcriptom hbv
specif rnai block viral transcript gener hbv cccdna
integr dna widespread coverag theori reduc viral replic cycl
product non-repl viral antigen produc integr dna
caus greater compar reduct hbsag compar cpam earli time point aro-
hbv also state arrowhead broad genotyp coverag would avoid potenti
develop resist
aro-hbv current on-going phase i/ii trial recruit chronic hbv patient
hbsag screen greater equal iu/ml date monthli dose three month
administ hbeag-posit neg patient
nuc-experienc nuc-nav patient either remain nuc therapi initi
nuc conjunct rnai result interpret monotherapi result
primari endpoint safeti trial also assess reduct hbsag baselin
post-dos nadir day interim data present aasld liver meet
novemb dose-depend respons six group experienc
decreas mean hbsag log day everi patient treat
experienc reduct least log exhibit hbv dna also declin log
nuc-nav patient typic would expect four month nuc
monotherapi howev hbv rna reduct appear strong cpam especi
compar day time point also reduct hepat core relat antigen
hbcrag -- viral protein product precore/cor gene mute comparison
biomark reduct regardless result suggest mechan success
block creation viral protein closer prove sustain virolog cure off-
treatment possibl earli cpam result
interim safeti result also posit subcutan inject
note associ mild inject site reaction aro-hbv patient also
headach vs nausea flu-lik symptom
strong reduct hbsag surpris view posit physician
catalyst encourag sign partnership up-front potenti
develop commerci mileston though rnai therapi could like produc
greater steeper hbsag declin cpam directli block format new cccdna
prevent integr hbv dna produc antigen ultim benefit true
patient outcom unknown increment impact surrog biomark
rnai could well reduc hbsag cccdna long-term elimin cccdna
reservoir hbsag product integr dna may rebound therapi unless immun
system clear infect liver cell could prevent lifelong rnai therapi
would like unten proposit patient benefit block hbsag
integr dna proven correl greater chanc hbsag loss
ultim class drug judg abil stop therapi prevent hbv
dna rebound
due life-long therapi requir lack cure
leerink take-away hbv market current declin peak categori sale
creat payer budget headroom high-pric novel mechan
declin cost come declin drug cost due generic
rel low treatment penetr new drug superior cur efficaci
would like expand elig patient popul fold increas size
market materi near term
global annual aggreg revenu hbv medicin current estim
annual sale declin past year peak
categori revenu estim exhibit histor hbv revenu estim includ
maximum estim annual sale pegasi indic hbv
hcv reach nearli peak annual sale recent declin hbv revenu driven
introduct gener nuc shift away pegasi due unfavor
benefit/risk profil overal base iqvia data appear number patient treat
nuc increas despit declin sale revenu almost patient current
treat pegasi peak categori revenu viread baraclud
blockbust drug gener sale use mani
patient us treatment
exhibit prior year global hbv sale
hbv market also achiev multi-billion-dollar histori low drug penetr rate
base polari observatori collabor estim less global chronic
hbv preval receiv antivir therapi chronic hbv patient world-wide
polari observatori collabor deem treatment-elig base estim risk statu
approxim treat exhibit
unit state polari observatori collabor estim patient
antivir therapi base increas prescript volum nuc note iqvia
trend increas number beneficiari viread baraclud
drug dashboard believ treat number hbv patient like increas
late exhibit
exhibit us monthli prescript hbv nuc
level treatment penetr us still mean one-third treatment-elig
patient therapi low estim chronic hbv us
preval activ treat therefor hbv market penetr room expand
includ treatment elig patient current guidelin expand
base low high estim total us chronic hbv preval respect exhibit
exhibit hbv treatment expans opportun us
observ prove multipl point relat assembl commerci opportun first
hbv market support pastand could futuremultipl blockbust drug
singl time assembl could easili compet multipl cpam mechan
still becom highli profit drug second declin global hbv revenu due gener
entri clear payer budget capac new therapi help ensur assembl
medicin receiv full valu increment benefit proven third market tremend
room expans inabl produc cure keep low risk patient low viral load
initi therapi mani high risk patient avoid therapi due lifetim treatment
oblig rel low perceiv benefit effect drug enter market would
expect increas drug penetr treatment-elig popul potenti
expans treatment-elig criteria encompass patient chronic hbv
leerink take-away relev market compar cur hcv market suggest
hbv market support multipl drug gener least growth total market
potenti all-or cure hbv trail initi develop launch all-or cure
hcv nearli decad first oral cure hcv sovaldi gilead approv
fda basi cure rate reach newer medicin cure
hcv sovaldi launch price treatment cours subsequ hcv
drug maintain similar price short level cost met immedi pushback
govern payer patient price per treatment sinc fallen
discount high price also led back-log treat patient routin deni
access medicin insur govern payer liver accumul certain
degre damag despit price access challeng global hcv revenu all-or
regimen debut grew steadili declin
estim impress peak categori sale revenu alreadi
challeng drug discount reach major year prior
advent oral cur treatment hcv us market potenti cur treatment
includ interferon ribavirin peak approxim introduct
cur treatment shorter treatment durat boost valu market peak
nearli
compar total sale brand drug indic hbv reach maximum
estim given year peak hcv revenu estim global hbv
revenu lower current global hcv revenu steady-st
treatment penetr reduc price lower peak global hcv revenu exhibit
exhibit all-or hcv annual sale compar peak combin brand hbv sale
geograph major peak sale opportun hcv deriv us
market past year peak annual sale all-or hcv regimen reach
us europ estim peak sale reach rest-of-world row
primarili japan estim peak sale reach similar exhibit given hbv
predominantli ex-u diseas us price power like closer ex-u
price hcv experi assum evenli distribut geograph revenu mix
leerink compani model valuat
leerink take-away forecast peak sale risk-
adjust probabl success assum multipl competit
entrant believ speed market superior profil allow
captur major share cur hbv market
valuat assembl stock base sole opportun and/or
follow-on cpam hbv market model use polari observatori collabor
epidemiolog estim forecast sale potenti four geographi us western
european countri japan china base data novel mechan releas date
model assum cpam rnai therapeut come market cur medicin
hbv model also assum cpam captur domin market share due
oral conveni like superior safeti profil given lack data cure rate either
mechan conserv forecast drug use current treatment-
elig popul patient nuc untreat patient high viral load
alreadi evid establish liver diseas
assum phase trial start complet year similar
recent phase trial vemlidi hbv assumpt impli launch us
first full-year sale delay launch europ japan one year
reason estim launch china take extra year us launch
similar delay observ sovaldi hcv assum first cpam
launch also forecast competitor cpam launch geographi one year
estim geograph penetr trend similar observ hcv
rel higher penetr us japan western european countri use
conserv estim treatment penetr china exhibit
exhibit leerink hbv model geograph launch penetr
overal estim cpam cumul use patient across
geographi year launch exhibit comparison sinc launch vertex
telaprevir estim base compani disclosur patient
